Silva Souza Adaliany Cecília da, Souza Marasca Giórgia de, Kretzmann-Filho Nélson Alexandre, Dall-Bello Aline, Alexandre Kliemann Dimas, Valle Tovo Cristiane, Gorini da Veiga Ana Beatriz
Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Programa de Pos-Graduação em Medicina: Hepatologia, Porto Alegre, RS, Brazil.
Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Programa de Pos-Graduação em Medicina: Hepatologia, Porto Alegre, RS, Brazil; Hospital Nossa Senhora da Conceição (HNSC), Porto Alegre, RS, Brazil.
Braz J Infect Dis. 2017 Sep-Oct;21(5):525-529. doi: 10.1016/j.bjid.2017.05.002. Epub 2017 Jun 9.
Infection by hepatitis B virus (HBV) is a worldwide public health problem. Chronic HBV infection with high viral replication may lead to cirrhosis and/or hepatocellular carcinoma. Mutant HBV strains, such as the HBV A1762T/G1764A double mutant, have been associated with poor prognosis and higher risk of the patient for developing cirrhosis and/or hepatocellular carcinoma. This study analyzed the presence of the HBV A1762T/G1764A double mutant in patients with chronic HBV and its association with clinical parameters such as viral load, aminotransferases, and HBV antigens. A total of 49 patients with chronic hepatitis B were included in the study, and the HBV A1762T/G1764A double mutant strain was detected in four samples (8.16%) by polymerase chain reaction followed by restriction fragment length analysis (PCR-RFLP). The viral load was not significantly different between patients with or without the double mutant strain (p=0.43). On the other hand, carriers of the HBV A1762T/G1764A double mutant had higher levels of ALT (p=0.0028), while AST levels did not differ between groups (p=0.051). In this study, 75% of the samples with the HBV A1762T/G1764A double mutation were HBeAg negative and anti-HBe positive, reflecting seroconversion even though they still displayed high viral loads. Our study has shown that the HBV A1762T/G1764A double mutant strain circulates in Brazilian patients, and is associated with elevated levels of ALT and HBeAg seroconversion.
乙型肝炎病毒(HBV)感染是一个全球性的公共卫生问题。高病毒复制的慢性HBV感染可能导致肝硬化和/或肝细胞癌。突变的HBV毒株,如HBV A1762T/G1764A双突变株,与预后不良以及患者发生肝硬化和/或肝细胞癌的较高风险相关。本研究分析了慢性HBV患者中HBV A1762T/G1764A双突变株的存在情况及其与病毒载量、转氨酶和HBV抗原等临床参数的关联。该研究共纳入49例慢性乙型肝炎患者,通过聚合酶链反应(PCR)及限制性片段长度分析(PCR-RFLP)在4份样本(8.16%)中检测到HBV A1762T/G1764A双突变株。有或无双突变株的患者之间病毒载量无显著差异(p=0.43)。另一方面,HBV A1762T/G1764A双突变株携带者的ALT水平较高(p=0.0028),而各组之间AST水平无差异(p=0.051)。在本研究中,具有HBV A1762T/G1764A双突变的样本中有75% HBeAg阴性且抗-HBe阳性,这表明即使病毒载量仍很高,但已发生血清学转换。我们的研究表明,HBV A1762T/G1764A双突变株在巴西患者中传播,并且与ALT水平升高及HBeAg血清学转换相关。